Cargando…

Opportunities and challenges in psychopharmacology


This review addresses novel approaches for influencing the transcriptome, the epigenome, the microbiome, the proteome, and the energy metabolome. These innovations help develop psychotropic medications which will directly reach the molecular targets, leading to beneficial effects, and which will be...

Descripción completa

Detalles Bibliográficos
Autor principal: Schulz, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Les Laboratoires Servier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787536/
https://www.ncbi.nlm.nih.gov/pubmed/31636486
http://dx.doi.org/10.31887/DCNS.2019.21.2/pschulz
_version_ 1783458285958987776
author Schulz, Pierre
author_facet Schulz, Pierre
author_sort Schulz, Pierre
collection PubMed
description This review addresses novel approaches for influencing the transcriptome, the epigenome, the microbiome, the proteome, and the energy metabolome. These innovations help develop psychotropic medications which will directly reach the molecular targets, leading to beneficial effects, and which will be individually adapted to provide more efficacy and less toxicity. The series of advances described here show that these once utopian goals for psychiatric treatment are now real themes of research, indicating that the future path for psychopharmacology might not be as narrow and grim as considered during the last few decades.

format Online
Article
Text
id pubmed-6787536
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Les Laboratoires Servier
record_format MEDLINE/PubMed
spelling pubmed-67875362019-10-21 Opportunities and challenges in psychopharmacology
 Schulz, Pierre Dialogues Clin Neurosci State of the Art This review addresses novel approaches for influencing the transcriptome, the epigenome, the microbiome, the proteome, and the energy metabolome. These innovations help develop psychotropic medications which will directly reach the molecular targets, leading to beneficial effects, and which will be individually adapted to provide more efficacy and less toxicity. The series of advances described here show that these once utopian goals for psychiatric treatment are now real themes of research, indicating that the future path for psychopharmacology might not be as narrow and grim as considered during the last few decades.
 Les Laboratoires Servier 2019-06 /pmc/articles/PMC6787536/ /pubmed/31636486 http://dx.doi.org/10.31887/DCNS.2019.21.2/pschulz Text en © 2019, AICH – Servier GroupCopyright © 2019 AICH – Servier Group. All rights reserved http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle State of the Art
Schulz, Pierre
Opportunities and challenges in psychopharmacology

title Opportunities and challenges in psychopharmacology

title_full Opportunities and challenges in psychopharmacology

title_fullStr Opportunities and challenges in psychopharmacology

title_full_unstemmed Opportunities and challenges in psychopharmacology

title_short Opportunities and challenges in psychopharmacology

title_sort opportunities and challenges in psychopharmacology

topic State of the Art
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787536/
https://www.ncbi.nlm.nih.gov/pubmed/31636486
http://dx.doi.org/10.31887/DCNS.2019.21.2/pschulz
work_keys_str_mv AT schulzpierre opportunitiesandchallengesinpsychopharmacology